Association of hepatitis B with antirheumatic drugs: a case–control study
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Though concern of hepatitis B virus (HBV) reactivation by antirheumatic agents has limited therapeutic opportunities in HBV-infected rheumatoid arthritis (RA) patients, the relative risks (RR) among such agents have not been clarified.
We compared the reporting of antirheumatic-agent-associated hepatitis B.
We assessed 92 hepatitis B cases and 98,069 controls from a population of 98,161 RA patients registered into the US Food and Drug Administration’s (FDA’s) adverse event database between 2004 and 2010.
A reporting odds ratio (ROR), a signal suggesting a risk for hepatitis B among antirheumatic agents, was measured.
Treatment with corticosteroids [ROR 2.3 (95 % confidence interval 1.3–4.0)], methotrexate [4.9 (3.9–6.0)], rituximab [7.2 (5.3–9.9)], tacrolimus [4.2 (1.5–11.9)], or reporting from Japan [2.2 (1.1–4.2)] were associated with higher signal, whereas adalimumab had a lower ROR [0.2 (0.1–0.4)].
There are known limitations of spontaneous reporting, such as underreporting, the Weber effect, reporting bias, indication bias, and limited clinical information such as HBV status.
Adalimumab’s low reporting rate is most likely be due to notoriety. However, the possibility that adalimumab might suppress reactivation of HBV cannot be denied. Until the possibility is clarified in well-designed clinical studies, physicians should use adalimumab cautiously in patients with HBV.
- Calabrese LH, Zein NN, Vassilopoulos D. Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies. Ann Rheum Dis. 2006;65(8):983–9. CrossRef
- Zingarelli S, Airo P, Frassi M, Bazzani C, Scarsi M, Puoti M. Prophylaxis and therapy of HBV infection in 20 patients treated with disease modifying antirheumatic drugs or with biological agents for rheumatic diseases. Reumatismo. 2008;60(1):22–7.
- Saag KG, Teng GG, Patkar NM, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 2008;59(6):762–84. CrossRef
- Fauci AS, Kasper DL, Longo DL, et al. Harrison’s principles of internal medicine. 17th Edition. New York: McGraw-Hill; 2008.
- Tamori A, Koike T, Goto H, et al. Prospective study of reactivation of hepatitis B virus in patients with rheumatoid arthritis who received immunosuppressive therapy: evaluation of both HBsAg-positive and HBsAg-negative cohorts. J Gastroenterol. 2011;46(4):556–64. CrossRef
- Mori S. Past hepatitis B virus infection in rheumatoid arthritis patients receiving biological and/or nonbiological disease-modifying antirheumatic drugs. Mod Rheumatol. 2011.
- Caporali R, Bobbio-Pallavicini F, Atzeni F, et al. Safety of tumor necrosis factor alpha blockers in hepatitis B virus occult carriers (hepatitis B surface antigen negative/anti-hepatitis B core antigen positive) with rheumatic diseases. Arthritis Care Res (Hoboken). 2010;62(6):749–54. CrossRef
- Vassilopoulos D, Apostolopoulou A, Hadziyannis E, et al. Long-term safety of anti-TNF treatment in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection. Ann Rheum Dis. 2010;69(7):1352–5. CrossRef
- Tsubouchi H, Kumada H, Kiyosawa K, et al. Prevention of immunosuppressive therapy or chemotherapy-induced reactivation of hepatitis B virus infection Joint report of the Intractable Liver Diseases Study Group of Japan and the Japanese Study Group of the standard antiviral therapy for viral hepatitis. Kanzo. 2009;50(1):38–42. CrossRef
- Oshima Y, Tojo A. Pulmonary alveolar hemorrhage possibly associated with lenalidomide use. Int J Hematol. 2011;94(3):296–7. CrossRef
- Oshima Y, Tojo A. Attractive tools for systematic case accumulation. Int J Hematol. 2011;94(4):413–4. CrossRef
- Murashige N, Tanimoto T, Oshima Y. Interstitial lung disease and gefitinib. N Engl J Med. 2010;363(16):1578–9. author reply 1579–80. CrossRef
- Oshima Y. Characteristics of drug-associated rhabdomyolysis: analysis of 8,610 cases reported to the US Food and Drug Administration. Intern Med. 2011;50(8):845–53. CrossRef
- Pariente A, Gregoire F, Fourrier-Reglat A, Haramburu F, Moore N. Impact of safety alerts on measures of disproportionality in spontaneous reporting databases: the notoriety bias. Drug Saf. 2007;30(10):891–8. CrossRef
- Umemura T, Kiyosawa K. Fatal HBV reactivation in a subject with anti-HBs and anti-HBc. Intern Med. 2006;45(12):747–8. CrossRef
- Lok AS, Liang RH, Chiu EK, Wong KL, Chan TK, Todd D. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology. 1991;100(1):182–8.
- Hass M, Hannoun C, Kalinina T, Sommer G, Manegold C, Gunther S. Functional analysis of hepatitis B virus reactivating in hepatitis B surface antigen-negative individuals. Hepatology. 2005;42(1):93–103. CrossRef
- Rothman KJ, Lanes S, Sacks ST. The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug Saf. 2004;13(8):519–23. CrossRef
- Yeo W, Johnson PJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology. 2006;43(2):209–20. CrossRef
- Cheng AL, Hsiung CA, Su IJ, et al. Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma. Hepatology. 2003;37(6):1320–8. CrossRef
- Ishikawa T, Kono D, Chung J, et al. Polyclonality and multispecificity of the CTL response to a single viral epitope. J Immunol. 1998;161(11):5842–50.
- Thimme R, Wieland S, Steiger C, et al. CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol. 2003;77(1):68–76. CrossRef
- Ando K, Moriyama T, Guidotti LG, et al. Mechanisms of class I restricted immunopathology. A transgenic mouse model of fulminant hepatitis. J Exp Med. 1993;178(5):1541–54. CrossRef
- Pfizer Japan Inc. Interview form for Eternelcept. In: http://www.info.pmda.go.jp/go/interview/2/671450_3999424G1025_2_1F. 18 ed. Tokyo, Japan; 2012.
- Mitsubishi Tanabe Pharma Corporation. Interview form for Infliximab. In: http://www.info.pmda.go.jp/go/interview/1/400315_2399402F1026_1_200_1F. 20 ed. Osaka, Japan; 2012.
- Abbott Japan Co. Ltd. Interview form for Adalimumab. In: http://www.info.pmda.go.jp/go/interview/1/100159_3999426G1024_1_005_1F. 5 ed. Tokyo, Japan; 2010.
- Strand V, Kimberly R, Isaacs JD. Biologic therapies in rheumatology: lessons learned, future directions. Nat Rev Drug Discov. 2007;6(1):75–92. CrossRef
- Ioannou GN. Hepatitis B virus in the United States: infection, exposure, and immunity rates in a nationally representative survey. Ann Intern Med. 2011;154(5):319–28. CrossRef
- Li S, Kaur PP, Chan V, Berney S. Use of tumor necrosis factor-alpha (TNF-alpha) antagonists infliximab, etanercept, and adalimumab in patients with concurrent rheumatoid arthritis and hepatitis B or hepatitis C: a retrospective record review of 11 patients. Clin Rheumatol. 2009;28(7):787–91. CrossRef
- Benucci M, Manfredi M, Mecocci L. Effect of etanercept plus lamivudine in a patient with rheumatoid arthritis and viral hepatitis B. J Clin Rheumatol. 2008;14(4):245–6. CrossRef
- Association of hepatitis B with antirheumatic drugs: a case–control study
Volume 23, Issue 4 , pp 694-704
- Cover Date
- Print ISSN
- Online ISSN
- Springer Japan
- Additional Links
- Hepatitis B
- Rheumatoid arthritis
- Antirheumatic drug
- Adverse event reporting system (AERS)
- Spontaneous report
- Industry Sectors
- Author Affiliations
- 1. The Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo, 108-8639, Japan
- 2. Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, 812-8582, Japan